Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Parkinson disease”

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruiting
NCT06989112Phase 3Updated Sep 3, 2026
Sponsor: AstraZeneca
Endometrial Cancer
United States, Australia, Austria, Belgium, Brazil +18 more
VG081821AC Tablets for Early to Mid-stage Parkinson's DiseaseRecruiting
NCT07725562Phase 2, Phase 3Updated Sep 3, 2026
Sponsor: Zhejiang Vimgreen Pharmaceuticals, Ltd.
Parkinson Disease (PD)
China
Neurofeedback Rehabilitation With FES and VR for PDCompleted
NCT06690931NAUpdated Sep 3, 2026
Sponsor: g.tec medical engineering GmbH
Parkinson Disease
Austria
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)Recruiting
NCT06445972Phase 1, Phase 2Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms · Esophageal Cancer
United States, Brazil, Chile, China, France +6 more
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)Terminated
NCT04246177Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular
United States, Australia, Brazil, Chile, China +22 more
Effect on Parkinson's Disease After Therapeutic Induction of CranioSacral Integrated TherapyEnrolling By Invitation
NCT01989013NAUpdated Sep 3, 2026
Sponsor: Zia, Al Raza
Parkinson's Disease
United States
Deep Brain Stimulation (DBS) Retrospective Outcomes StudyRecruiting
NCT03664609N/AUpdated Sep 3, 2026
Sponsor: Boston Scientific Corporation
Parkinson Disease · Essential Tremor · Dystonia
United States, Belgium, France, Germany, Italy +1 more
Psilocybin Therapy for Depression and Anxiety in Parkinson's DiseaseCompleted
NCT04932434Phase 2Updated Sep 3, 2026
Sponsor: Joshua Woolley, MD, PhD
Parkinson Disease · Depression · Anxiety
United States
Physiology, Imaging and Modeling of Essential TremorCompleted
NCT03811405NAUpdated Sep 3, 2026
Sponsor: University of Florida
Essential Tremor · Parkinson Disease · Dystonia
United States
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Recruiting
NCT06966700Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +34 more
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)Recruiting
NCT06841354Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Belgium, Brazil +30 more
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)Recruiting
NCT07216703Phase 3Updated Sep 3, 2026
Sponsor: Merck Sharp & Dohme LLC
Cervical Cancer
United States, Argentina, Austria, Belgium, Brazil +23 more
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's DiseaseRecruiting
NCT06976268Phase 2, Phase 3Updated Sep 3, 2026
Sponsor: Biohaven Therapeutics Ltd.
Parkinson Disease
United States
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseActive Not Recruiting
NCT04691661Phase 2Updated Sep 3, 2026
Sponsor: Il-Yang Pharm. Co., Ltd.
Parkinson Disease
France
Split-belt Treadmill Training for Freezing of Gait in Parkinson's DiseaseCompleted
NCT05511597NAUpdated Sep 3, 2026
Sponsor: KU Leuven
Parkinson Disease · Freezing of Gait · Split-belt Treadmill
Belgium
Connectomic Guided DBS for Parkinson's DiseaseEnrolling By Invitation
NCT06618157NAUpdated Sep 3, 2026
Sponsor: Duke University
Parkinson Disease · Tremor · Dyskinesias
United States
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)Recruiting
NCT07252739Phase 2Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Malignant Neoplasm
United States, Chile, China, Finland, Greece +8 more
PechaKucha Versus PowerPoint for Parkinson's Disease Education in NursesCompleted
NCT07800312NAUpdated Sep 2, 2026
Sponsor: Istanbul University - Cerrahpasa
Nursing Education
Turkey (Türkiye)
Sensor-Based Optimization of Therapy for Parkinson's Disease Patients With Motor FluctuationsNot Yet Recruiting
NCT07074119NAUpdated Sep 2, 2026
Sponsor: Assistance Publique - Hôpitaux de Paris
Parkinson Disease (PD)
France
Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's DiseaseCompleted
NCT04506073Phase 2Updated Sep 2, 2026
Sponsor: Mya Schiess
Parkinson's Disease
United States
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)Active Not Recruiting
NCT06049212Phase 1Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer · Solid Tumors · Programmed Cell Death-1 (PD1, PD-1) · Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
Japan
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)Recruiting
NCT06596746N/AUpdated Sep 2, 2026
Sponsor: Casa di Cura San Raffaele Cassino
Neurodegenerative Diseases · Parkinson Disease · Synucleinopathies · Lewy Body Disease
Italy
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Recruiting
NCT06469944Phase 1, Phase 2Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms · Esophageal Cancer
United States, Brazil, Chile, China, France +7 more
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)Recruiting
NCT05319730Phase 1, Phase 2Updated Sep 2, 2026
Sponsor: Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
United States, Brazil, Chile, China, Germany +9 more
The GBA Multimodal Study in Parkinson's DiseaseCompleted
NCT04101968N/AUpdated Sep 2, 2026
Sponsor: Pacific Parkinson's Research Centre
Parkinson Disease · GBA Gene Mutation · Gaucher Disease
United States, Canada

Previous page Next page